Falling asleep to your favorite show doesn't have to ruin your sleep, experts say
You've heard the rule: No TV before bed.
But many people find that it helps them fall asleep if they listen to something –– audiobooks, music, podcasts or TV shows.
A 2018 study found that more than half of people with sleep disturbances use music as a sleep aid.
It is poor sleep hygiene to look at screens to scroll or watch a show before bedtime, but what if you aren't looking, just listening?
'It's like Goldilocks,' said sleep medicine specialist Dr. Rachel Salas, professor of neurology at the Johns Hopkins University School of Medicine in Baltimore. 'It's a matter of what works for you … It's not only the practices of your bedtime routine, but your environment, all the things.'
Everyone is different, and some people might get great sleep if they fall asleep listening to something, Salas said. However, there are some practices to keep in mind to make sure you are maximizing the benefits and avoiding potential pitfalls.
Winding down to sleep
The key to listening to audiobooks, podcasts, music or TV to fall asleep is making sure it is helping you wind down instead of waking you up, said Dr. Shalini Paruthi, sleep medicine attending physician at John J. Cochran Veterans Hospital in St. Louis and adjunct professor at St. Louis University School of Medicine.
'If listening to something actually keeps a person more engaged or awake and therefore replaces sleep time, this can be detrimental to health,' she said in an email. 'It is recommended that adults obtain at least 7 hours of sleep regularly for optimal performance.'
On the other hand, a predictable kind of noise can help tell your body it's time to wind down, Salas added.
'If you find that that's part of your bedtime routine, and it's kind of comforting and relaxing … that's great,' she said.
Try choosing content to listen to that will allow you to transition into sleep, added Dr. Lindsay Browning, a psychologist and sleep expert in Berkshire in the United Kingdom.
'Choose something not too engaging so that your brain isn't motivated to stay awake and fight sleep to pay attention to it,' she said in an email.
A sleep story may be a better choice than audio of a book you want to read. Shows you have heard before and know how they end might be better than falling asleep to a nailbiter.
When to turn the sound off
A soundtrack for sleep might help you get to sleep, but it doesn't always keep you asleep if it keeps going all night, Browning said.
'It's important to set an auto timer to mute the sounds as soon after falling asleep as possible,' she said.
If the show, podcast, or music you are playing has unexpected noises, frequencies or volumes, it might alert your brain to pay attention, Salas said. The startling noise doesn't always wake you up fully, but it can cause many little awakenings you aren't aware of. That will disturb your sleep nonetheless, she added.
One steady sound, like white noise or ASMR, can help your sleep quality, especially if you live in a noisy area, Salas added.
'(If) bars close at a certain time and people are outside, walking home and talking or yelling, that's going to disrupt your sleep,' she said.
A consistent and non-alarming noise can stifle those kinds of ambient noise, she said.
What to do about insomnia
Sometimes listening to something to fall asleep isn't just a nice part of a bedtime routine –– it's a way to quiet racing thoughts at night. Some proactive steps during the day may help, Browning said.
'If you find that your brain is too active as you try to fall asleep, which keeps you awake, you could try to address those busy thoughts and worries earlier in the day,' she said.
Methods include having a dedicated time earlier in the day to think about those worries or utilizing cognitive shuffling, a technique that involves thinking up random and non-emotionally charged words to take your mind off of your racing thoughts, Browning said.
'It's a much better idea to try to learn ways of quieting a busy mind at night that don't require you to mask those unwanted thoughts with an external sound,' Browning said.
If you are using listening to something to help with insomnia and it doesn't seem to help after a two-to-four-week period, it might be time to see a board-certified sleep physician and get to the root of the problem, Paruthi said.
'There are several proven therapies that work well for insomnia treatment such as cognitive behavior therapy for insomnia, or when appropriate, medications can be considered,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
3 myths about metabolism could be holding you back
Think speeding up your metabolism is key to losing weight? Metabolism has grown into one of the biggest buzzwords in the wellness industry — a tricky code that, if deciphered, is believed to unlock the secrets of weight loss and overall health. Despite the term's ubiquity, one scientist says many people don't understand much of how this basic bodily process works. 'They think it has something to do with how much food we can eat without gaining weight or something like that,' Dr. Kevin Hall told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently on his podcast, Chasing Life. Hall wants to elevate metabolism for different reasons. 'Metabolism is just this incredible biochemical process that basically turns the food that we eat and the oxygen that we breathe into essentially … everything we are and everything we do,' he said. A leading nutrition and metabolism scientist, Hall is well-known for his research on contestants from the reality show 'The Biggest Loser' that helped explain what set participants who kept the weight off apart from those who gained it back. He spent more than two decades at the National Institutes of Health. His later work on ultraprocessed foods investigated its link to obesity, including one study that demonstrated it actively caused participants to overeat. Hall announced his early retirement and exit from NIH in April, citing censorship of how his research findings were communicated. He's now coauthor of the new book 'Food Intelligence: The Science of How Food Both Nourishes and Harms Us' alongside journalist Julia Belluz. Metabolism and weight loss enter conversations arm in arm, but this, according to Hall, can be reductive. 'I just find it incredibly frustrating sometimes that this idea of metabolism, this really beautiful physiological process that is so fundamental to life, is kind of talked about as, 'Oh well, if you take this supplement, you can boost your metabolism and lose weight,'' he explained to Gupta. Is a faster or higher metabolism really the highway to weight loss? Hall is here to set the record straight, highlighting three misconceptions about metabolism that show there is more to it than meets the eye. Myth 1: People with obesity have slow metabolisms One common belief is that a slower metabolism results in a higher body weight. But mostly, Hall said, the opposite is true. 'Generally, larger people have faster metabolisms than smaller people,' he told Gupta. Hall attributed the pervasiveness of this myth to the way researchers designed early metabolism studies. Scientists initially tried to match up participants' caloric intake to their weight, but they didn't account for the fact that these calorie counts were self-reported. It turned out that those with obesity often underreported the number of calories they ate to a larger degree than their leaner counterparts. This, Hall said, 'led people to a conclusion that, well, if they're eating less calories and they're maintaining their weight, then they must be burning less calories. And maybe the reason why they have obesity is because they have slow metabolisms.' Modern technology now allows researchers to rely on data, not participants' own reports. 'When we actually directly measure people's metabolisms, people with obesity have higher metabolic rates on average than people who are lean,' Hall noted. But the myth that we should be boosting metabolism to treat obesity has stubbornly persisted — and has at times led to deadly consequences. When Stanford University researchers discovered that the chemical compound 2,4-dinitrophenol, or DNP, increased metabolism levels in the 1930s, they enthusiastically promoted it as a safe and effective tool for treating obesity. While DNP did boost metabolism, it also led to side effects that included blindness and death, causing federal drug regulators to quickly withdraw it from the market. 'Maybe,' Hall suggested, 'it shouldn't be too much of a surprise later to realize that with something so fundamentally important to life as metabolism, you can't just turn it up and turn it down with a pharmaceutical drug and not expect some pretty severe side effects, including death.' Myth 2: Metabolism slows down as we age Like weight, age might not affect metabolism as much as you may assume. 'It turns out that until you get to very advanced ages, we're talking 70s and 80s, it looks like our metabolic rate is roughly constant,' Hall said. There are, of course, changes in the aging body that can impact metabolic rates. People 'past the age of 30 or so,' Hall said, are 'tending to lose muscle mass or tending to lose lean mass, and they're tending to gain fat mass. And that alone is anticipated to result in a lower metabolism.' That's because lean muscle burns more calories than fat. But it's these age-related changes — that are not inevitable — and not age itself, that influence one's metabolism. 'Once you get rid of that effect … it doesn't seem like there's a fundamental aging effect to slow metabolism as, as we get older,' Hall concluded. A couple ways to combat the loss of lean muscle mass as you age is by engaging in twice-a-week strength training and getting enough protein in your diet (but no need to go overboard). Myth 3: A high metabolism is necessary for weight loss Another pillar of metabolism mythology is the idea that a slow metabolism is the enemy of continued weight loss. Interventions such as dieting are believed to slow metabolism to the point that you can't lose any additional weight. But keeping your metabolism from slowing down isn't the key to sustained weight loss, Hall said. In fact, it's just the opposite. 'The people who are most successful at losing weight and keeping it off are the ones who sport the slowest metabolisms or the greatest reductions in metabolism,' he said. 'It's kind of like stretching a spring, right?' The more intensely someone diets or exercises, the more weight they'll lose and the more their metabolism will slow down, he explained in his book. Hall's research showed that a slower metabolism 'didn't seem to determine anyone's ability to lose weight or keep it off in the short or long run.' By uncoupling metabolism from the weight loss conversation, Hall said he hopes everyone can appreciate the phenomenon for what it really is. Misinformation about metabolism 'has really distracted people, I think, from the real beauty of what this is,' he told Gupta. 'It's harnessing the continuous flow of matter and energy in our food and in our breath and powering every cell in our body, as well as the bodies and cells of practically every organism that we have ever encountered,' Hall said. 'It's a fundamental component of life, and it's just incredibly fascinating.'
CTV News
13 hours ago
- CTV News
‘Just scary': Family of Sask. man bitten by rattlesnake in Texas raising funds to bring him home
A Swift Current man remains in critical but stable condition after being bitten by a rattlesnake in Texas. Daniel Fehr, who lives in Texas for his job, was bitten on his left ankle by a rattlesnake during a round of golf on July 27. He was on the seventh hole at the course with a couple of friends when it happened. His family says a short time later, the bite triggered an allergic reaction that led to anaphylactic shock and eventually to cardiac arrest. Fehr was then admitted to intensive care in Odessa, Texas. His wife, Stephanie, who lives in Swift Current, told CTV News she felt like something was wrong right away after not hearing from her husband for an unusually long period of time. 'My husband called me 100 times a day, and he said he would call me when he was done golfing, and I was like, 'Oh, he should be done by now,'' Fehr said. 'Something didn't feel right. My youngest son and I checked his location and it was moving rapidly on the map, and I was just like, 'What was going on?'' Expand Autoplay 1 of 8 Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Daniel Fehr (Photo courtesy: Payton Fehr) Her fears were confirmed when Daniel's phone location shifted to a hospital. Once she found out he was undergoing immediate treatment, Stephanie and her two youngest kids drove to Montana hoping to catch the soonest flight to Texas, but with limited options, they decided to make the entire drive, more than 2,500 kilometres from their Swift Current home. 'Every time he's home, the dad jokes never stop,' Daniel's daughter Payton said. 'When he's not home, he's always sending us jokes, and is always calling us to know what we're doing. And then when he's home, he'll always take the boys golfing.' Stephanie describes Payton as 'mini-Danny,' and credits her for her strength and support amid an unimaginable situation. In the days since the bite, Daniel has undergone several procedures, including a tracheostomy. His family says many of his organs have stabilized, but questions remain over a possible brain injury, caused by swelling. Daniel Fehr (Photo courtesy: Payton Fehr) Stephanie says Daniel's medical status is still day-to-day, as the family spends nearly all of their time at his side in hospital, waiting for updates. 'Our whole world is lying in a hospital bed,' said Stephanie. 'We don't know what the future is going to bring for us. It's scary, I don't wish this on anybody.' 'Us kids are definitely going to grow up a lot faster so quickly,' said Payton. 'My brother stepped in as the man in the house. He's helping pay for things and provide. And then my little brother is just growing up too quickly.' Their situation is made worse by Daniel's lack of insurance in the United States, creating an additional layer of financial pressure for the family. A GoFundMe has been created for the Fehr family to help with Daniel's medical expenses and his transportation back to Saskatchewan, a major priority for Stephanie. 'We need to get him home. We don't have the funds to do so, it's just scary,' said Stephanie. 'If something goes bad, I don't want to have to deal with that here. We want him home. He'd be so mad at himself right now. He thought he was invincible, and apparently he's not. 'We just are really relying on the kindness of strangers. Saskatchewan is a wonderful place, and I'm just hoping they can rally to help our family somehow,' she added. As of Friday afternoon, the fundraiser had surpassed $12,000.
Globe and Mail
14 hours ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
